Valuation: Biogen Inc.

Market Cap 29.4B 25.72B 23.72B 21.91B 41.57B 2,804B 42.27B 283B 111B 1,381B 110B 108B 4,749B P/E 2026 *
30.3x
P/E 2027 * 16.7x
Enterprise Value 34.91B 30.54B 28.17B 26.01B 49.36B 3,330B 50.19B 337B 132B 1,640B 131B 128B 5,639B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 3.16x
Free-Float
85.96%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week-8.87%
Current month+4.55%
1 month+4.55%
3 months+16.99%
6 months+7.82%
Current year+15.52%
1 week 173.22
Extreme 173.22
193
1 month 173.22
Extreme 173.22
193
Current year 134.7
Extreme 134.7
193
1 year 103.75
Extreme 103.75
193
3 years 99
Extreme 99
255.6
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 2022-11-13
Director of Finance/CFO 60 2025-02-28
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 69 2010-03-22
Director/Board Member 77 2009-12-31
Director/Board Member 72 2019-06-18
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%-8.87% - - 29.4B
-0.51%+1.57%+17.05%-7.30% 67.61B
-5.16%-8.63%+38.70%+203.59% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-48.99%-53.63% 40.94B
-10.83%-14.41%+102.94%-44.10% 27.09B
-1.53%-0.13%+70.16%+85.73% 23.32B
+3.88%+2.16%+11.36%+192.66% 19.89B
-1.59%-1.63%+64.87%+130.98% 16.91B
-4.75%+11.27%+84.83%+382.26% 16.84B
Average -1.74%-0.90%+42.27%+103.30% 34.13B
Weighted average by Cap. -1.54%-1.58%+32.61%+74.23%

Financials

2026 *2027 *
Net sales 10.05B 8.79B 8.11B 7.49B 14.22B 959B 14.45B 96.92B 38.06B 472B 37.75B 36.93B 1,624B 10.38B 9.08B 8.38B 7.74B 14.68B 990B 14.93B 100B 39.31B 488B 38.99B 38.14B 1,677B
Net income 1.49B 1.31B 1.21B 1.11B 2.11B 143B 2.15B 14.41B 5.66B 70.23B 5.61B 5.49B 241B 1.97B 1.72B 1.59B 1.47B 2.78B 188B 2.83B 18.98B 7.45B 92.51B 7.39B 7.23B 318B
Net Debt 5.51B 4.82B 4.44B 4.1B 7.79B 525B 7.92B 53.1B 20.85B 259B 20.68B 20.23B 890B 3.38B 2.96B 2.73B 2.52B 4.79B 323B 4.87B 32.63B 12.81B 159B 12.71B 12.43B 547B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
26-07-10 €173.22 -0.05% 30
26-07-09 €173.30 -9.12% 0
26-07-06 €190.70 +0.33% 55
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
199.15USD
Average target price
222.83USD
Spread / Average Target
+11.89%

Quarterly revenue - Rate of surprise